Alvotech Prices $151.85M Combined Public Offering and Private Placement at $3.75 Per Share
ALVO sits 32% above its 52-week low of $2.94 on elevated volume (8.5× avg).
Summary
Alvotech has priced a combined public offering and concurrent private placement, raising $143.72 million in net proceeds by issuing 40.49 million shares at $3.75 each. This substantial capital raise, while dilutive, is intended to fund biosimilar development and general corporate needs.
Key Events · Financing and Capital Events · ALVO
-
Public Offering Priced
Alvotech is offering 22,666,667 ordinary shares at a public offering price of $3.75 per share, generating gross proceeds of approximately $85.0 million.
-
Concurrent Private Placement
The company entered into agreements for a concurrent private placement of 17,826,666 ordinary shares at the same $3.75 per share price, for gross proceeds of approximately $66.85 million.
-
Substantial Capital Raise
The combined offerings are expected to generate total net proceeds of approximately $143.72 million, providing significant capital for the company.
-
Significant Share Dilution
The issuance of 40,493,333 new shares represents a dilution of approximately 12.97% to existing shareholders, based on shares outstanding as of March 31, 2026.
Analysis · ALVO · Life Sciences
This filing finalizes the terms and pricing of the previously announced public offering and concurrent private placement. The company is raising a substantial $143.72 million in net proceeds by issuing 40.49 million new shares at $3.75 per share, a discount to the prior day's closing price of $4.24. This capital infusion, representing nearly 12% of the company's market capitalization, is crucial for funding biosimilar development and general corporate purposes, especially given recent regulatory challenges. However, it will result in significant dilution for existing shareholders.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALVO was trading at $3.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.94 to $9.94. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.